Chris Karrasch, MD
Orthopaedic Surgery · Nephi, UTNPI 1225323744
Payments from drug & device makers
Across 52 payments — averaging $77.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$3K
- Catalyst Orthoscience$504
- Exsomed Corporation$161
- Miach Orthopaedics, Inc.$145
- Linvatec Corporation$98
- Advanced Orthopaedic Solutions, Inc.$91
- plus $234 from 10 others
What the payments were for
- Travel & lodging$2,58064%
- Food & beverage$1,44536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 34 | $2,793 |
| Catalyst Orthoscience | 2 | $504 |
| Exsomed Corporation | 1 | $161 |
| Miach Orthopaedics, Inc. | 1 | $145 |
| Linvatec Corporation | 1 | $98 |
| Advanced Orthopaedic Solutions, Inc. | 1 | $91 |
| Boston Scientific | 1 | $58 |
| Vericel Corporation | 3 | $49 |
| Davol Inc. | 1 | $22 |
| Stryker | 1 | $19 |
| Smith+Nephew | 1 | $16 |
| Innovation Technologies Inc | 1 | $16 |
| Merck | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Anika Therapeutics, Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Persona$828
- ROSA-Knee$550
- Oxford$358
- Archer CSR Total Shoulder System$336
- Archer R1 Reverse Shoulder System$336
- INnate Implant$322
- InFrame Implant$161
- ArrowPhix System$161
- ArcPhix System$161
- ROSA$155
- Comprehensive Shoulder$107
How this compares
$4,025 in reported general payments places this provider in the 40th percentile of 221 orthopaedic surgery providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 123 | $734 |
| Meloxicam | 139 | $629 |
| Ondansetron Hcl | 79 | $524 |
| Cyclobenzaprine Hcl | 97 | $466 |
| Omeprazole | 58 | $303 |
| Celecoxib | 14 | $234 |
| Diclofenac Sodium | 11 | $203 |
| Tramadol Hcl | 24 | $99 |
| Ibuprofen | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Nephi
- Hugh WestMurray$14.2M
- Aaron HofmannSalt Lake City$10.7M
- Armen KhachatryanWest Jordan$3.9M
- Thomas CaltonWashington Terrace$3.5M
- Jeremy GilillandSalt Lake City$3.3M
- Robert TashjianSalt Lake City$3M
- Joshua HickmanBountiful$2.7M
- Jeffrey JacksonSalt Lake City$2.3M
- Peter StevensSlc$2.1M
- Brandon LawrenceSalt Lake City$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.